Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other Billionaire Ken Fisher’s healthcare stock picks with massive upside potential.

Lilly has an Earnings ESP of -14.61% and a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Per our proven model, companies with the ...

HSBC cut its rating to "reduce" from "buy," and slashed its price objective Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from ...

Eli Lilly (LLY) shares dip after HSBC double downgraded the stock to reduce — a sell-equivalent rating — from buy, saying the drugmaker’s risk-reward “is not attractive.” - Peloton ...

Chief executives from Nvidia, Johnson & Johnson, Eli Lilly, General Electric and SoftBank Group are among the corporate leaders slated to visit the White House on April 30, as US President Donald ...

Novo is following in the footsteps of competitor Eli Lilly, which began selling its obesity drug Zepbound with telehealth companies at a lower cost last year.

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion. If the $12.50-per-share all-cash deal is completed, it will give ...

Novo Nordisk and Eli Lilly have started offering their treatments at lower prices of around $350 to $700 a month, but that’s still unaffordable for many patients. “This is kind of like a ...